Advanced heart MRI and CT to find hidden clots after cryptogenic stroke in people with left ventricular disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational project that uses cardiac CT (CCT) and cardiac MRI (CMR) in addition to standard transthoracic echocardiography to look for intracardiac thrombi in patients with embolic stroke of undetermined source (ESUS) who also have left ventricular disease. Eligible patients are adults with non-lacunar acute ischemic stroke meeting ESUS criteria and features of left ventricular disease (for example ejection fraction 30–49%, wall motion abnormalities, or ventricular dilation). The study compares findings from advanced imaging against standard workup to determine how often CCT/CMR identify potential ventricular thrombi or other cardiac sources missed by TTE. By systematically capturing imaging and clinical data, the project aims to improve embolic risk stratification and inform whether changes in secondary prevention (for example anticoagulation) might be warranted.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 85 years Modified Rankin Scale (mRS) score ≤ 4 Diagnosis of acute ischemic stroke (detected by CT or brain MRI) Diagnosis of ESUS according to standard criteria
* Stroke detected by CT or MRI that is not lacunar. Lacunar is defined as a subcortical infarction (including pons and mesencephalon) in the distribution of the small penetrating cerebral arteries, with a maximum size ≤ 1.5 cm on CT or ≤ 2.0 cm on diffusion-weighted MRI images (\< 1.5 cm on T2-weighted MRI images). Excluded: multiple small deep infarcts, lateral bulb infarcts, cerebellar infarcts, patients with clinical lacunar stroke syndrome and no visible infarction on imaging.
* Absence of extracranial or intracranial atherosclerosis causing ≥ 50% stenosis in the artery supplying the ischemic area. Vascular imaging of the extracranial and intracranial vessels is required using angiography, CT angiography (CTA), MR angiography (MRA), or color Doppler ultrasound, at the discretion of the treating physician and local principal investigator.
* No major cardioembolic source identified, including permanent or paroxysmal atrial fibrillation (AF), sustained atrial flutter, intracardiac thrombus (\*as specified above, these patients will be recruited in phase 1 of the study only if an isolated ventricular thrombus is found without other major cardiac causes), mechanical heart valve prosthesis, atrial myxoma or other cardiac tumors, moderate or severe mitral stenosis, recent myocardial infarction (\< 4 weeks), left ventricular ejection fraction (EF) \< 30%, valve vegetations or infective endocarditis.
* No other identified cause of stroke (such as arteritis, dissection, migraine, vasospasm, drug abuse, hypercoagulability, etc.)

Presence of LVD defined by at least one of the following criteria:

* Moderately reduced left ventricular (LV) systolic function, defined as EF 30-49%.
* LV wall motion abnormalities (LVWMAs), defined as hypokinetic, akinetic, or dyskinetic segments of the left ventricular wall not associated with recent or acute myocardial infarction (within 4 weeks).
* LV aneurysm
* Enlarged LV with or without spontaneous contrast
* Non-compacted LV, with deep trabeculations or spongy LV
* Cardiomyopathies, such as restrictive cardiomyopathy, hypertrophic cardiomyopathy, or cardiac amyloidosis

Patients capable of signing informed consent (IC) or, in the case of unconscious patients without an authorized legal representative, recruited in a "Deferred" mode

Exclusion Criteria:

* Major cardioembolic sources, as specified in the ESUS criteria Patients with a thrombophilic state secondary to active cancer, defined as "diagnosis of solid or hematologic malignant tumor within 6 months of stroke, ongoing oncological treatment, or hematologic cancer not in remission." Patients with ipsilateral carotid plaques to the ischemic stroke considered at high risk: thrombus on the wall, floating thrombus, ulcerated plaque.

Patients under 60 years of age with a high-risk patent foramen ovale (PFO) and stroke classified as "probable" PFO-associated stroke according to the PASCAL classification.

Pregnancy or puerperium. Contraindication to MRI and CT with contrast agents

Where it's running

• ASST Grande Ospedale Metropolitano Niguarda
  Milan, Lombardy, Italy Recruiting

Study contacts

• Principal investigator: Angelo Cascio Rizzo, MD — ASST Grande Ospedale Metropolitano Niguarda
• Study coordinator: Angelo Cascio Rizzo, MD
• Email: angelo.casciorizzo@ospedaleniguarda.it
• Phone: +390264442348

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing PFO closure and anticoagulants for stroke prevention in older patients

  This study is testing whether closing a small hole in the heart combined with certain medications is better than just using medications alone to prevent strokes in older patients who are at high risk.

  Recruiting at 42 sites Phase 3 Assistance Publique - Hôpitaux de Paris · Amiens and 41 other locations · NCT05387954

• Left atrial function in people with unexplained (cryptogenic) stroke.

  This will see if lower left atrial strain on a heart ultrasound is linked to unexplained (cryptogenic) stroke and to higher risk of another stroke in adults who had a stroke without a known cause.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07224178

• Using smartwatches to detect atrial fibrillation after cryptogenic stroke

  This study is testing if smartwatches can help find atrial fibrillation in people who have had a stroke with no known cause, to prevent future strokes.

  Recruiting Technical University of Munich · Munich · NCT06005233

• Long-term outcomes after PFO closure at Severance Hospital

  This registry tests how well percutaneous PFO closure works over the long term and what factors predict residual shunt, new atrial fibrillation, or other outcomes in adults who had the procedure.

  Recruiting Yonsei University · Seoul · NCT07724171

• P3 Occluder System for closing a heart opening (PFO) after stroke

  We are testing the P3 Occluder System to see if it safely and effectively closes a patent foramen ovale in adults who had a stroke related to their heart opening.

  Recruiting Recross Cardio, Inc. · Belgrade · NCT07698951

• Percutaneous repair of the atrial septum using the P3 Occluder System for PFO closure

  This trial tests the P3 Occluder System to close a patent foramen ovale (PFO) in adults 18–65 who have had a stroke that may be linked to their PFO.

  Recruiting at 5 sites Recross Cardio, Inc. · Los Angeles, California and 4 other locations · NCT07172464

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.